ReviewCurrent cardiology reports2026
Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review highlights differences in pathophysiologic mechanisms, diagnostic challenges and therapeutic responses of heart failure with preserved ejection fraction (HFpEF) in women. RECENT
findingsEmerging research provides further insight into the pathophysiology of HFpEF in women, and the role of obesity and its impact on treatment. Other theories highlight the role of microvascular dysfunction in women with HFpEF. Gender differences in cardiac imaging parameters for assessment of diastolic dysfunction and elevated filling pressures may require refinement for improved diagnostic accuracy of HFpEF in women. HFpEF is fast becoming the dominant form of heart failure in the US and women have double the lifetime risk of developing HFpEF compared with heart failure with reduced ejection fraction. Gender-specific diagnostic parameters and treatment options have been hindered by low participation of women in cardiovascular trials. Increased participation in larger scale trials and further investigations into sex-specific pathophysiology are needed for improved outcomes in women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.